HEOR

News

NICE backs wider tumour profiling use in early breast cancer

Three tests that can be used to profile tumours in people with breast cancer and predict whether they will respond to chemotherapy have been cleared for wider use by the N

News

Price cut unlocks NHS use of sickle cell drug Oxbryta

It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after a

News

NICE backs Novartis duo for NHS use in young glioma patients

An oral therapy that can allow children and adolescents with an aggressive form of brain cancer to be treated at home rather than in hospital has been recommended for use

News

NICE backs wider NHS use of multiple myeloma drug Nexpovio

More than 1,000 people with incurable blood cancer multiple myeloma could be eligible for treatment with Menarini Stemline UK’s Nexpovio after NICE backed NHS use of the d

News

NICE backs AbbVie’s oral therapy for migraine prevention

AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic and episodic migraine prevention to be recommended by NICE for NHS patients in England and W

News

Pfizer’s Velsipity heading for NHS use in ulcerative colitis

Up to 25,000 people with ulcerative colitis (UC) in England could be in line for treatment with Pfizer’s once-daily oral therapy Velsipity, after NICE recommended its use

NICE backs wider tumour profiling use in early breast cancer

Price cut unlocks NHS use of sickle cell drug Oxbryta

NICE backs Novartis duo for NHS use in young glioma patients

NICE backs wider NHS use of multiple myeloma drug Nexpovio

NICE backs AbbVie’s oral therapy for migraine prevention

Pfizer’s Velsipity heading for NHS use in ulcerative colitis

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

HEOR

Editor's Picks